Figure 2.

a) Cell viabilities and b) hemolysis rates of the MQ₂T, MQ₂T₂, and MQ₃T₂ microparticles at various concentrations (n = 3–4). c) BCI index (n = 3), d) adherent platelet number (n = 4) and e) CD62P content of whole blood (n = 3) treated with the gauze, MQ₂T, MQ₂T₂ and MQ₃T₂ groups. f) HGB content of adherent RBCs in the gauze, MQ₂T, MQ₂T₂, and MQ₃T₂ groups after incubation with diluted whole blood (photographs are inserted) (n = 3). g) Representative photographs of bone apertures (blue circle indicates bone defect area and white circle indicates residual bone wax) and h) HGB contents (n = 3–7) of whole blood samples in the Blank, Bone wax and MQ₂T₂ groups during Day 0–7. i) H&E staining analysis of the defected bone samples in the Blank, Bone wax and MQ₂T₂ groups at Day 4 (white circle indicates bleeding sites, yellow arrow indicates inflammation‐associated cells and red arrow indicates repaired blood vessels). Data are presented as the mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 among the marked groups using multiple t tests.